| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.96B | +103.7% |
| Gross profit | ¥0.65B | — |
| Operating income | ¥0.37B | — |
| Net income | ¥0.33B | +180.2% |
| Gross margin | 33.1% | Net margin 16.6% |
| Revenue Q/Q | +4.5% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.31B | 66.9% |
| R&D | ¥0.11B | 5.6% |
| SG&A | ¥0.16B | 8.4% |
| Tax & other | ¥0.04B | 2.1% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
诚达药业 ・ 朗威股份 ・ 国泰环保 ・ 联特科技 ・ 三元生物 ・ 华兰疫苗 ・ 中亦科技 ・ 联合化学 ・ 金杨精密 ・ 亨迪药业 ・ 联盛化学 ・ 观想科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies